Report Contents
Market Overview
The global Exocrine Pancreatic Insufficiency (EPI) market is generating revenue of approximately USD 3.60 Billion in 2025 and is expected to advance to about USD 3.87 Billion in 2026, supported by a projected compound annual growth rate of 7.60% through 2032. This growth trajectory reflects rising diagnosis rates of chronic pancreatitis and cystic fibrosis, increased adoption of pancreatic enzyme replacement therapy, and expanding access to gastroenterology services in emerging healthcare systems.
As the competitive landscape intensifies, scalability of manufacturing, intelligent localization of treatment protocols, and deep technological integration across diagnostics, digital adherence tools, and real-world data platforms emerge as core strategic imperatives. Converging trends such as precision dosing, value-based reimbursement models, and patient-centric care pathways are expanding the scope of the EPI market and redefining its future direction beyond traditional enzyme formulations. Against this backdrop, this report serves as an essential strategic tool, providing forward-looking analysis to guide critical investment decisions, identify high-value opportunities, and anticipate regulatory and competitive disruptions shaping the next phase of industry transformation.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Exocrine Pancreatic Insufficiency (EPI) Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Exocrine Pancreatic Insufficiency (EPI) Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Pancreatic enzyme replacement therapy:
Pancreatic enzyme replacement therapy (PERT) currently represents the dominant segment within the Exocrine Pancreatic Insufficiency market, accounting for a significant portion of prescription therapies and payer reimbursement flows. These formulations, typically combining lipase, amylase and protease, have become the standard of care for patients with EPI arising from chronic pancreatitis, cystic fibrosis and pancreatic surgery, which collectively drive a substantial share of treatment volumes. Given that the overall EPI market is projected to reach about 3.60 Billion in 2025 and 3.87 Billion in 2026, with a compound annual growth rate of 7.60% toward approximately 6.01 Billion by 2032 according to ReportMines, PERT products are expected to capture the majority of this expansion due to entrenched clinical guidelines and established prescriber familiarity.
The competitive advantage of PERT lies in its clinically validated ability to normalize fat absorption and reduce steatorrhea, with modern enteric-coated formulations often achieving fat digestion efficiencies exceeding 80% when dosed appropriately in conjunction with meals. This high efficacy, combined with predictable pharmacokinetics and well-characterized safety profiles, enables PERT to reduce hospitalization risk and nutrition-related complications, thereby supporting lower overall care costs per patient over time. In economic evaluations, optimized PERT regimens frequently generate meaningful reductions in unplanned acute care use and nutrition support expenses, which strengthens formulary positioning and contracting leverage versus emerging alternatives.
The primary catalyst for growth in the PERT segment is the rising prevalence and improved diagnosis of chronic pancreatitis and post-pancreatic surgery EPI in aging populations across North America, Europe and parts of Asia-Pacific. Parallel trends, including greater screening in cystic fibrosis centers and increasing use of cross-sectional imaging that incidentally detects pancreatic atrophy, are expanding the addressable patient pool and driving earlier treatment initiation. Additionally, incremental improvements in capsule design, dosing flexibility and patient support programs are enhancing adherence and real-world outcomes, reinforcing PERT’s central role as the backbone therapy in EPI management.
-
Non-porcine and novel enzyme therapies:
Non-porcine and novel enzyme therapies form a rapidly emerging segment of the Exocrine Pancreatic Insufficiency landscape, targeting patients who require alternatives to conventional porcine-derived products for religious, ethical or immunologic reasons. Although this segment currently represents a smaller share of the overall market compared with traditional PERT, it is positioned for above-average growth as biopharmaceutical developers advance recombinant, microbial and plant-based lipase platforms through clinical development. In the context of a market growing at 7.60% annually toward about 6.01 Billion by 2032, non-porcine solutions are expected to capture an expanding niche, particularly in regions where dietary and cultural restrictions are highly influential in therapy selection.
The competitive advantage of these non-porcine and novel enzyme therapies lies in their differentiated source materials and potential for more precise engineering of enzymatic activity profiles. Recombinant and microbial enzymes can be optimized for stability across variable gastric pH conditions and may achieve comparable or improved fat absorption rates relative to standard porcine products while offering improved batch consistency. In some development programs, manufacturing processes aim for double-digit percentage reductions in production variability and impurity burdens, which can translate into more consistent clinical performance and reduced risk of supply disruptions that impact patient adherence.
The main growth catalysts for this segment include increasing regulatory and societal focus on animal-free and ethically sourced pharmaceuticals, alongside advances in protein engineering and fermentation technology that lower cost of goods over time. Expanding investment in rare disease and specialized gastrointestinal pipelines is also catalyzing partnerships between biotechnology firms and larger pharma companies to co-develop non-porcine EPI therapies for global distribution. As health systems and payers seek flexible contracting strategies, these novel products may also benefit from value-based agreements that reward improvements in nutritional status, body weight stabilization and reduction in gastrointestinal symptom burden in EPI populations.
-
Adjunctive gastrointestinal therapies for exocrine pancreatic insufficiency:
Adjunctive gastrointestinal therapies for Exocrine Pancreatic Insufficiency encompass proton pump inhibitors, prokinetics, bile acid modulators and gastrointestinal mucosal protectants that are used alongside PERT to optimize digestive function. While these agents are not specific to EPI, they play a meaningful role in a significant portion of complex cases where gastric acidity, altered motility or concomitant malabsorptive conditions reduce the effectiveness of enzyme replacement alone. Within the broader EPI market that is moving toward 3.87 Billion in 2026, adjunctive therapies contribute incremental revenue streams and help differentiate comprehensive care protocols offered by integrated specialty centers.
The competitive advantage of adjunctive therapies stems from their ability to enhance the bioavailability and intraluminal performance of pancreatic enzymes, thereby improving symptom control without necessarily increasing PERT doses. For example, acid suppression with appropriately titrated proton pump inhibitors can significantly reduce enzyme degradation in the stomach, leading to measurable improvements in stool fat excretion metrics and patient-reported outcomes. By limiting the need to escalate enzyme capsule counts, adjunctive strategies can keep daily pill burden and associated drug costs more manageable, which is an important driver of long-term adherence in chronic therapy.
The primary growth catalyst for adjunctive gastrointestinal therapies in EPI is the increasing recognition of multifactorial maldigestion and the shift toward personalized digestive health regimens. As gastroenterologists use more sophisticated diagnostics, including pH monitoring, bile acid breath tests and small bowel imaging, they identify additional pathophysiologic contributors that can be targeted with non-enzymatic agents. This trend, combined with the growing presence of multidisciplinary pancreatic disease clinics, supports more frequent integration of adjunctive therapies into treatment algorithms and opens opportunities for pharmaceutical companies to position existing gastrointestinal products with EPI-specific clinical data and education initiatives.
-
Diagnostic and monitoring solutions for exocrine pancreatic insufficiency:
Diagnostic and monitoring solutions for Exocrine Pancreatic Insufficiency include fecal elastase tests, direct pancreatic function tests, breath tests and emerging non-invasive imaging and biomarker platforms. This segment plays a pivotal role in expanding the treated patient base by enabling earlier and more accurate identification of EPI in individuals with vague gastrointestinal symptoms or overlapping conditions such as irritable bowel syndrome and celiac disease. As awareness grows and more patients are funneled into appropriate treatment pathways, diagnostic segments indirectly support revenue growth across therapeutic categories within the 3.60 Billion to 6.01 Billion market trajectory outlined by ReportMines.
The competitive advantage of advanced diagnostic and monitoring tools lies in their ability to quantify exocrine function and track response to therapy, which facilitates better dosing precision and reduces the risk of under-treatment or over-treatment. Modern fecal elastase assays offer high sensitivity for moderate to severe EPI, and when combined with clinical scoring systems, they can significantly improve diagnostic yield compared with symptom-based assessment alone. Emerging digital platforms that integrate test results with dietary tracking and adherence data can provide clinicians with actionable insights, potentially cutting time-to-optimized dosing by meaningful margins and improving health-related quality of life metrics.
The primary growth catalyst for this segment is the global shift toward value-based gastroenterology care, where payers and providers increasingly focus on objective outcomes, avoidable hospitalizations and cost-effective use of pharmacotherapy. Expanded screening of high-risk cohorts, such as patients with longstanding diabetes, pancreatic cancer, bariatric surgery history or chronic alcohol-related pancreatitis, is generating additional demand for reliable EPI diagnostics. In parallel, ongoing innovation in point-of-care testing and home-based sample collection kits is improving patient convenience and test completion rates, thereby strengthening this segment’s role as a foundational enabler of efficient EPI management pathways worldwide.
Market By Region
The global Exocrine Pancreatic Insufficiency (EPI) market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents a core revenue hub for the Exocrine Pancreatic Insufficiency market, anchored by advanced gastroenterology infrastructure and high diagnosis rates for chronic pancreatitis and cystic fibrosis–related EPI. The region benefits from strong reimbursement frameworks and rapid uptake of premium pancreatic enzyme replacement therapies, supporting a sizable share of the projected USD 3,60 Billion global market in 2025 and its 7.60% CAGR trajectory toward 2032.
The United States and Canada jointly drive regional demand, with tertiary care centers and specialized pancreatology clinics acting as key prescribing nodes. Despite this maturity, significant potential remains in earlier diagnosis through primary-care integration, tele-gastroenterology for remote populations, and optimized adherence programs. Challenges include high therapy costs, insurance coverage variability, and under-recognition of EPI in mild chronic pancreatitis, which together constrain full penetration of evidence-based dosing regimens.
-
Europe:
Europe holds a substantial portion of global EPI revenues, characterized by a broad base of national health systems and strong clinical guidelines that standardize pancreatic enzyme replacement therapy use. Major markets such as Germany, the United Kingdom, France, Italy, and Spain act as regional anchors, supported by high procedural volumes in pancreatic surgery and oncology, which increases demand for long-term enzyme supplementation.
The region contributes a stable, mature revenue stream while still offering incremental growth through improved recognition of EPI in bariatric surgery, pancreatic cancer survivorship, and elderly malnutrition management. Untapped potential lies in Eastern and Southern Europe, where underdiagnosis and limited specialist access reduce therapy uptake. Addressing reimbursement disparities, harmonizing dosing protocols, and expanding diagnostic capacity in secondary hospitals are critical steps to unlock additional volume-driven growth within the European market.
-
Asia-Pacific:
The broader Asia-Pacific region, excluding individually analyzed Japan, Korea, and China, is emerging as a high-growth frontier for the Exocrine Pancreatic Insufficiency market. Countries such as India, Australia, Singapore, and Southeast Asian nations are experiencing rising incidences of chronic pancreatitis, post-surgical pancreatic complications, and diabetes-related pancreatic dysfunction that collectively expand the addressable patient pool.
Although the region currently accounts for a smaller share of the global market compared with North America and Europe, its contribution to incremental global growth is significant over the 2025–2032 period. Key opportunities involve enhancing diagnostic awareness among general practitioners, expanding access to quality-assured pancreatic enzyme formulations, and leveraging digital health tools for nutrition monitoring. Challenges include pricing sensitivity, uneven reimbursement, limited specialist density outside metropolitan centers, and variability in product quality among local manufacturers.
-
Japan:
Japan is a strategically important, highly regulated EPI market with strong adoption of guideline-driven therapy, contributing a meaningful share of Asia-Pacific revenues. Its aging population, high prevalence of pancreatic and upper gastrointestinal malignancies, and sophisticated hospital network generate consistent demand for prescription-strength pancreatic enzyme products and nutrition management services.
The market is relatively mature but still offers growth through earlier EPI detection in mild chronic pancreatitis and post-gastrectomy patients, as well as optimization of dosing to improve fat absorption and quality of life. Untapped potential remains in smaller regional hospitals and clinics, where underdiagnosis persists due to limited use of fecal elastase testing. Key challenges include strict pricing controls, budget pressures within the national health insurance system, and the need to demonstrate cost-effectiveness of higher-dose or novel formulations.
-
Korea:
South Korea plays a growing role in the EPI landscape, supported by advanced tertiary hospitals, strong endoscopy capabilities, and increasing awareness of pancreatic disorders among gastroenterologists. The country’s expanding burden of pancreatic cancer, chronic alcohol-related pancreatitis, and metabolic syndrome creates a rising need for reliable pancreatic enzyme replacement therapies and structured nutritional support.
While Korea currently represents a modest portion of global revenues, its high healthcare digitalization and centralized insurance system provide an efficient platform for rapid therapy uptake once clinical pathways are standardized. Untapped potential is concentrated in community hospitals and outpatient settings, where EPI symptoms are often misattributed to irritable bowel syndromes or functional dyspepsia. Challenges include limited patient education, constrained formularies for some enzyme products, and the need for more local real-world evidence to support broader reimbursement.
-
China:
China is one of the most dynamic high-growth markets for Exocrine Pancreatic Insufficiency, with rising incidence of pancreatitis, pancreatic surgery, and gastrointestinal oncology driven by lifestyle shifts and population aging. Large urban centers such as Beijing, Shanghai, and Guangdong lead adoption of advanced diagnostic methods and imported pancreatic enzyme brands, creating strong demand concentration in tier-one hospitals.
Despite this, a significant portion of the EPI patient population in lower-tier cities and rural provinces remains undiagnosed or undertreated, representing a major untapped opportunity. The country’s increasing healthcare expenditure and expansion of basic medical insurance formulary coverage can accelerate penetration of standardized EPI therapies. Key challenges involve price pressures from centralized procurement, disparities in specialist availability between regions, limited awareness among primary-care physicians, and the need for locally manufactured, cost-effective enzyme formulations that still meet international quality standards.
-
USA:
The United States is the single largest national market within the global Exocrine Pancreatic Insufficiency industry and a primary driver of the forecast increase from USD 3,60 Billion in 2025 to USD 6,01 Billion by 2032. High diagnosis rates in cystic fibrosis centers, advanced pancreatic surgery programs, and robust clinical trial activity underpin significant utilization of branded pancreatic enzyme replacement therapies.
The U.S. market is mature yet continues to grow at a healthy pace, supported by improved life expectancy in cystic fibrosis, greater recognition of EPI in diabetes and obesity-related pancreatic dysfunction, and strong commercial promotion. However, substantial unmet needs persist among underinsured patients, rural communities, and minority populations, where access to specialists and consistent therapy may be limited. Key challenges include high list prices, insurance prior authorization hurdles, patient adherence issues, and the need to integrate nutrition counseling with pharmacologic therapy to capture the full clinical and economic benefit.
Market By Company
The Exocrine Pancreatic Insufficiency (EPI) market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
AbbVie Inc.:
AbbVie plays a central role in the Exocrine Pancreatic Insufficiency market through its established pancreatic enzyme replacement therapy portfolio and deep presence in gastroenterology and cystic fibrosis care pathways. The company benefits from long-standing relationships with specialist prescribers, integrated patient-support programs, and strong reimbursement capabilities across major markets in North America and Europe. This positioning allows AbbVie to influence treatment algorithms, guideline adoption, and formulary placement in EPI management.
In 2025, AbbVie’s EPI-related revenue is estimated at USD 0.78 Billion with a corresponding market share of 21.70% . These figures indicate that AbbVie is one of the largest stakeholders in a global EPI market projected at USD 3.60 Billion in 2025, and they highlight its scale advantages in manufacturing, supply chain reliability, and payer negotiations. The company’s robust share also reflects strong brand recognition and physician trust in its pancreatic enzyme formulations.
AbbVie’s competitive differentiation in EPI is driven by its expertise in high-quality enzyme formulations, consistent bioavailability profiles, and investments in patient adherence tools such as dosing calculators, titration guides, and digital monitoring solutions. The firm leverages cross-portfolio synergies in immunology and specialty care to negotiate broader access agreements that include EPI therapies, creating a bundled value proposition that is difficult for smaller competitors to match. In addition, AbbVie continues to explore incremental formulation improvements and real-world evidence studies to demonstrate long-term outcomes, which helps reinforce premium positioning in increasingly cost-conscious health systems.
-
Nestle Health Science:
Nestle Health Science occupies a distinctive position in the EPI market at the intersection of medical nutrition and pharmaceutical-grade therapies. The company focuses on supporting patients with malabsorption and chronic gastrointestinal disorders, integrating pancreatic enzyme therapies with specialized nutritional formulations. This combination enables Nestle Health Science to address not only enzyme deficiency but also broader issues such as weight loss, micronutrient deficits, and impaired quality of life in EPI patients.
For 2025, Nestle Health Science’s EPI-focused revenue is estimated at USD 0.47 Billion with a global market share of approximately 13.10% . These metrics underline the company’s status as a top-tier player with strong representation in hospital outpatient clinics, cystic fibrosis centers, and nutrition-focused care pathways. Its scale allows efficient distribution of both prescription therapies and adjunct nutrition products across multiple regions, including Europe, Latin America, and Asia-Pacific, where awareness and diagnosis of EPI are steadily improving.
Nestle Health Science differentiates itself by integrating evidence-based nutrition science with enzyme replacement therapy, often collaborating with gastroenterologists and dietitians to build comprehensive therapy protocols. The company invests in clinical research on fat absorption, stool normalization, and growth outcomes in pediatric patients, which supports the clinical credibility of its offerings. Through strong key-account management in hospitals and specialized centers, and by providing education on dose titration and meal-related dosing strategies, Nestle Health Science secures a durable competitive edge versus manufacturers that focus solely on enzyme capsules without nutritional integration.
-
Allergan plc:
Allergan, prior to integration into larger pharmaceutical structures, held a meaningful role in gastrointestinal and specialty therapies, including Exocrine Pancreatic Insufficiency. Within the EPI market, the company built its presence through prescription pancreatic enzyme products that benefited from its established relationships with gastroenterologists and its experience in managing chronic digestive conditions. The brand equity of Allergan’s gastroenterology portfolio supports continued utilization of its EPI therapeutics in many regions.
In 2025, Allergan’s EPI-related revenue is estimated at USD 0.29 Billion and its market share at 8.10% . These figures suggest a solid second-tier position, with sufficient scale to remain competitive but without the dominance of the largest incumbents. The company’s share reflects durable prescription volumes in mature markets, stable formulary placements, and ongoing clinician familiarity with its enzyme formulations.
Allergan’s competitive advantages in EPI stem from its historical strengths in branded specialty medicines, experience with lifecycle management, and patient-centric programs. The company has emphasized consistent product quality, reliable supply, and clear dosing information, which are crucial in conditions such as EPI where under-dosing or inconsistent access can quickly degrade patient outcomes. Even as market dynamics evolve, the legacy of Allergan’s clinical engagement, continuing medical education initiatives, and post-marketing safety monitoring helps it retain relevance within the pancreatic enzyme replacement segment.
-
Pancreatic Enzyme Products Inc.:
Pancreatic Enzyme Products Inc. operates as a niche specialist in the Exocrine Pancreatic Insufficiency market, with a focused portfolio centered on high-quality enzyme replacement formulations. Unlike diversified pharmaceutical conglomerates, this company dedicates its resources primarily to pancreatic health and digestive disorders, allowing it to respond quickly to clinician feedback and evolving patient needs. Its specialized nature aligns well with centers of excellence in cystic fibrosis, chronic pancreatitis, and post-surgical pancreatic care.
For 2025, Pancreatic Enzyme Products Inc. is estimated to generate EPI-related revenue of USD 0.14 Billion with a global market share around 3.80% . While this scale is smaller than that of diversified multinationals, it remains significant within a USD 3.60 Billion market and underscores the company’s relevance in specific geographies and sub-segments. Its market presence is especially notable in settings where clinicians prefer highly specialized manufacturers and value detailed technical support.
The company’s strategic advantage lies in deep technical expertise in enzyme sourcing, enteric coating technologies, and batch-to-batch consistency, which are critical for maintaining predictable lipase, amylase, and protease activity in vivo. Pancreatic Enzyme Products Inc. also differentiates itself through responsive medical information services, close collaboration with specialty pharmacies, and targeted education on optimizing dosing based on fat intake. These capabilities allow the company to compete effectively on quality and service even when facing larger firms with broader commercial infrastructures.
-
Aptalis Pharma Inc.:
Aptalis Pharma Inc. has long been associated with therapies for gastrointestinal and cystic fibrosis-related conditions, positioning it naturally within the Exocrine Pancreatic Insufficiency landscape. The company’s EPI portfolio benefits from its heritage in developing modified-release formulations and high-potency enzyme products that address severe malabsorption. This specialization makes Aptalis a recognized name in many EPI treatment protocols, especially in North America and selected European markets.
In 2025, Aptalis Pharma’s EPI revenue is estimated at USD 0.32 Billion with a market share of about 8.80% . These levels place the company among the stronger mid-sized competitors, with enough market penetration to negotiate effectively with payers and maintain robust distribution networks. The market share underscores sustained demand for its formulations in both adult and pediatric EPI populations, particularly among patients requiring high-dose regimens.
Aptalis differentiates itself through formulation science, focusing on optimally sized enteric-coated microspheres and granules that mix well with food and provide reliable enzyme release in the duodenum. The company also emphasizes real-world outcomes, supporting data collection on weight stabilization, symptom control, and reduction in steatorrhea. Its targeted field force, specialized medical liaison teams, and partnerships with cystic fibrosis foundations and pancreatology societies help Aptalis maintain strong clinical visibility and reinforce its reputation as a technology-driven EPI specialist.
-
Digestive Care Inc.:
Digestive Care Inc. is a focused gastroenterology company that plays a meaningful role in the Exocrine Pancreatic Insufficiency segment by offering enzyme replacement therapies tailored to patient convenience and adherence. Its portfolio often appeals to clinicians who prioritize flexible dosing, palatable formulations, and options that accommodate complex meal patterns and pediatric use. This specialization makes the company particularly relevant in community-based gastroenterology practices and cystic fibrosis clinics.
For 2025, Digestive Care Inc. is projected to achieve EPI-related revenue of USD 0.11 Billion and a market share near 3.10% . While modest in absolute terms, these figures signify a stable foothold in the market and demonstrate that a significant portion of prescribers value its differentiated product attributes. The company’s revenue base provides sufficient scale to sustain targeted R&D and patient-support investments, even without the diversification of large pharmaceutical groups.
The firm’s competitive strengths include its close engagement with gastroenterologists and dietitians, emphasis on clear patient education materials, and product designs that facilitate accurate dose titration with meals and snacks. Digestive Care Inc. often concentrates on addressing practical barriers such as pill burden, swallowing difficulties, and variability in fat content across meals, all of which are critical to successful EPI management. By focusing on these real-world challenges and maintaining agile operations, the company carves out a resilient niche amid intense competition from multinational manufacturers.
-
Janssen Pharmaceuticals Inc.:
Janssen Pharmaceuticals Inc., as part of a global healthcare group, leverages a broad clinical and commercial infrastructure that extends into the EPI market. While EPI is not its primary therapeutic area, Janssen’s engagement in gastrointestinal, metabolic, and inflammatory diseases offers cross-disciplinary expertise that supports its role in pancreatic health. This enables Janssen to integrate EPI management into wider care pathways for complex chronic patients.
In 2025, Janssen’s EPI-related revenue is estimated at USD 0.18 Billion with a market share of approximately 5.00% . These levels reflect a meaningful, though not dominant, presence, indicating that Janssen competes effectively in selected markets and institutional accounts. Its share demonstrates that payers and providers recognize the reliability of its manufacturing and the clinical value of its therapies in specific patient segments.
Janssen’s strengths in EPI derive from its extensive clinical development capabilities, pharmacovigilance systems, and ability to generate real-world evidence across large patient populations. The company can utilize advanced analytics, adherence-monitoring tools, and integrated patient-support programs developed in other therapeutic areas to enhance outcomes for EPI patients. Additionally, Janssen’s reputation for quality and safety, combined with global market access expertise, allows it to maintain competitive positioning even in regions with stringent regulatory and reimbursement requirements.
-
Nordmark Pharma GmbH:
Nordmark Pharma GmbH is a critical upstream and downstream player in the Exocrine Pancreatic Insufficiency space, known both for its role in enzyme supply and for its own branded pancreatic enzyme products. The company’s deep experience in biological raw materials and enzyme extraction technologies positions it as a core partner within the EPI value chain, supporting other manufacturers as well as marketing its own therapies.
For 2025, Nordmark’s EPI-focused revenue is estimated at EUR 0.15 Billion with a corresponding market share of 4.20% . This scale reflects not only direct product sales but also the value generated through strategic supply relationships and contract manufacturing activities. The company’s participation in multiple points of the value chain enhances its resilience to pricing pressure in any single segment of the market.
The key competitive advantage for Nordmark lies in its specialized expertise in pancreatin production, stringent quality control processes, and regulatory compliance across numerous jurisdictions. Its capabilities in producing high-purity, consistent enzyme active ingredients are essential for ensuring predictable therapeutic performance across pancreatic enzyme replacement therapies. By combining this technical strength with selected branded offerings, Nordmark maintains strategic relevance and bargaining power in the EPI ecosystem, even when competing with much larger pharmaceutical companies.
-
Dr. Falk Pharma GmbH:
Dr. Falk Pharma GmbH is widely recognized in Europe as a specialist in gastroenterology and hepatology, which naturally extends to its role in the Exocrine Pancreatic Insufficiency market. The company focuses on prescription products that address chronic digestive disorders, enabling it to maintain close relationships with gastroenterology clinics and academic centers. Its scientific reputation and focus on digestive health help it maintain high levels of clinician trust.
In 2025, Dr. Falk Pharma’s EPI-related revenue is estimated at EUR 0.13 Billion with a global market share of roughly 3.60% . This performance underscores its strong regional presence, particularly in Germany and other European countries where specialized gastroenterology networks are well-developed. The company’s market share suggests that a significant portion of EPI prescriptions in these markets flows through its brands, especially for patients managed in specialist settings.
Dr. Falk’s competitive edge arises from its narrow therapeutic focus, continuous scientific engagement, and commitment to evidence-based medicine. The company invests in clinical trials and observational studies that document symptom relief, nutritional recovery, and long-term disease control in patients using its products. This research-oriented approach, combined with high service levels and educational programs for gastroenterologists, allows Dr. Falk Pharma to maintain premium positioning and defend market share against both global and regional competitors.
-
Chiesi Farmaceutici S.p.A.:
Chiesi Farmaceutici S.p.A. is an Italian-based international pharmaceutical company with a strong footprint in respiratory and rare diseases, and it has extended this expertise into Exocrine Pancreatic Insufficiency, particularly in cystic fibrosis-related cases. The company’s focus on high-need patient populations and specialized hospital channels aligns well with the complex management requirements of EPI.
For 2025, Chiesi’s EPI-related revenue is projected at EUR 0.17 Billion and its market share at around 4.70% . These figures indicate a solid and growing presence, especially in Europe and selected international markets where the company already has a strong hospital-focused infrastructure. The market share suggests that Chiesi is increasingly viewed as a reliable partner in comprehensive cystic fibrosis and chronic pancreatitis care.
Chiesi’s strategic advantage in EPI comes from its experience with orphan and niche indications, patient-centric clinical trial design, and integrated support services that encompass adherence support, home care coordination, and nutritional guidance. The company leverages these capabilities to deliver value beyond the pill, positioning its pancreatic enzyme therapies as components of holistic disease management programs. This approach enhances its competitive differentiation and enables deeper penetration in specialized centers that manage complex EPI cases.
-
Eurofarma Laboratorios S.A.:
Eurofarma Laboratorios S.A. is a major pharmaceutical player in Latin America and contributes meaningfully to the EPI market across the region through its portfolio of gastrointestinal and metabolic therapies. The company focuses on expanding access to high-quality medicines, including pancreatic enzyme replacement therapies, in markets where underdiagnosis of EPI is still common but gradually improving thanks to better awareness and diagnostic capacities.
In 2025, Eurofarma’s EPI-related revenue is estimated at USD 0.12 Billion with a market share of about 3.30% . These figures highlight the company’s regional strength rather than global dominance, reflecting its emphasis on Brazil and neighboring countries. Within these markets, however, Eurofarma holds a significant share of EPI prescriptions and often serves as a primary supplier in public and private healthcare systems.
Eurofarma’s competitive positioning is reinforced by its deep understanding of Latin American regulatory environments, pricing dynamics, and distribution challenges. The company actively collaborates with local medical societies to improve recognition of EPI symptoms in patients with chronic pancreatitis, diabetes, and post-surgical complications. By combining cost-competitive pricing with acceptable quality standards and reliable supply, Eurofarma supports broader patient access to enzyme replacement therapy and strengthens its long-term strategic relevance in the region.
-
Sun Pharmaceutical Industries Ltd.:
Sun Pharmaceutical Industries Ltd. is one of the largest generics and specialty pharmaceutical companies globally and plays a significant role in providing cost-effective pancreatic enzyme products, particularly in Asia and emerging markets. Its entry into the EPI market supports greater affordability and widens access in countries where branded imported products may be financially out of reach for many patients.
For 2025, Sun Pharma’s EPI-related revenue is projected at USD 0.16 Billion with a market share of approximately 4.40% . This level of participation demonstrates that the company has secured a meaningful foothold in the global EPI landscape, primarily through volume-driven strategies and competitive pricing. Its revenue base reflects high prescription volumes in price-sensitive markets where demand for pancreatic enzyme replacement therapy is rising due to improved diagnostic practices.
Sun Pharma’s competitive edge in EPI is built on its large-scale manufacturing capacity, experience in regulated markets, and ability to produce high-quality generics that meet global standards. The company can leverage its extensive distribution networks and hospital tender capabilities to win contracts for enzyme products across multiple geographies. By combining affordability with regulatory compliance and a broad product basket, Sun Pharma can bundle EPI therapies alongside other essential medicines, enhancing its bargaining power with payers and procurement agencies.
-
Akcea Therapeutics Inc.:
Akcea Therapeutics Inc., originally focused on rare and genetic metabolic disorders, plays a more emerging and innovation-driven role in the Exocrine Pancreatic Insufficiency market. Rather than concentrating on conventional enzyme replacement alone, the company’s capabilities lie in nucleic acid therapeutics and targeted approaches that may indirectly address conditions contributing to EPI or complement existing enzyme therapies in complex patient populations.
In 2025, Akcea’s direct EPI-related revenue is estimated at USD 0.05 Billion with a market share of around 1.40% . These modest figures reflect its status as a niche and innovation-oriented participant rather than a high-volume manufacturer of enzyme replacement products. Nonetheless, even a limited share in a growing USD 3.60 Billion market suggests that Akcea’s specialized technologies resonate in specific rare-disease segments where EPI coexists with complex metabolic pathologies.
Akcea’s differentiation lies in its advanced research platforms, partnerships with larger biopharmaceutical companies, and ability to explore novel mechanisms that could redefine long-term management of underlying diseases associated with EPI. While its short-term commercial footprint in enzyme therapy is relatively small, its innovation pipeline and expertise in rare disease networks position it as a potential future collaborator or acquisition target for larger firms seeking next-generation solutions in pancreatic and metabolic disorders.
-
AstraZeneca plc:
AstraZeneca plc is a global biopharmaceutical leader with major franchises in cardiovascular, respiratory, oncology, and metabolic diseases, and it participates in the EPI ecosystem primarily through its broader involvement in pancreatic and gastrointestinal disorders. Its role in EPI is more complementary than central, focusing on managing underlying conditions such as pancreatic cancer and chronic pancreatitis, which frequently lead to pancreatic exocrine insufficiency.
In 2025, AstraZeneca’s EPI-specific revenue is projected at USD 0.09 Billion with an estimated market share of 2.50% . This performance indicates a limited but strategically relevant presence, where enzyme-related offerings and supportive therapies are integrated into comprehensive care pathways. The company’s share underscores its capability to influence treatment standards indirectly through its leadership in related disease areas and its collaborations with oncology and gastroenterology centers.
AstraZeneca’s competitive advantage in the EPI context stems from its strengths in clinical science, real-world data analytics, and integrated care models for complex chronic diseases. The company can leverage multidisciplinary programs that combine oncology, pain management, nutrition, and supportive care, ensuring that EPI is recognized and treated as part of holistic patient management. This systems-level approach can translate into opportunities for co-developing or co-promoting pancreatic enzyme therapies, thereby expanding its influence without relying solely on direct EPI product sales.
-
Eli Lilly and Company:
Eli Lilly and Company contributes to the Exocrine Pancreatic Insufficiency market primarily through its deep expertise in diabetes, metabolic disorders, and gastrointestinal complications related to endocrine dysfunction. EPI often coexists with long-standing diabetes and pancreatic endocrine insufficiency, which allows Lilly to play an important role in identifying at-risk patients and integrating EPI assessment into metabolic care pathways.
For 2025, Eli Lilly’s EPI-related revenue is estimated at USD 0.10 Billion with a market share around 2.80% . Although this makes EPI a relatively small portion of Lilly’s overall portfolio, the contribution is strategically relevant because it complements its leadership in diabetes and obesity therapeutics. The market share reflects targeted deployment of enzyme-related solutions in specialized clinics and coordinated care programs for complex metabolic patients.
Lilly’s competitive differentiation in EPI lies in its strong relationships with endocrinologists, diabetologists, and primary care providers who manage patients at high risk for pancreatic insufficiency. By integrating screening for malabsorption and unexplained weight loss into chronic disease management protocols, Lilly can help expand the diagnosed EPI population and thereby support demand for enzyme replacement therapies. Its capabilities in digital health, remote monitoring, and patient-engagement platforms can also be adapted to optimize adherence and dose titration in EPI, reinforcing its value proposition in this growing, 7.60% CAGR market.
Key Companies Covered
AbbVie Inc.
Nestle Health Science
Allergan plc
Pancreatic Enzyme Products Inc.
Aptalis Pharma Inc.
Digestive Care Inc.
Janssen Pharmaceuticals Inc.
Nordmark Pharma GmbH
Dr. Falk Pharma GmbH
Chiesi Farmaceutici S.p.A.
Eurofarma Laboratorios S.A.
Sun Pharmaceutical Industries Ltd.
Akcea Therapeutics Inc.
AstraZeneca plc
Eli Lilly and Company
Market By Application
The Global Exocrine Pancreatic Insufficiency (EPI) Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Cystic fibrosis-associated exocrine pancreatic insufficiency:
Cystic fibrosis-associated EPI represents one of the most established application segments, with a high proportion of individuals with cystic fibrosis requiring lifelong pancreatic enzyme replacement to maintain growth, pulmonary resilience and overall survival. The core business objective in this segment is to convert historically high morbidity in pediatric and young adult populations into stable, predictable chronic care trajectories that reduce acute exacerbations and nutrition-related complications. As the global EPI market advances toward 3.60 Billion in 2025 and 3.87 Billion in 2026, cystic fibrosis accounts for a significant portion of high-intensity, continuous therapy utilization, making it strategically important for manufacturers seeking durable, long-duration treatment cohorts.
Adoption is strongly justified by quantifiable clinical and operational outcomes, as optimized enzyme therapy in cystic fibrosis can improve fat absorption to above 85% in many patients, leading to measurable gains in body mass index, lung function preservation and reduced hospitalization frequency. These performance improvements translate into lower per-patient inpatient days and enhanced treatment adherence, driving favorable return-on-investment for payers that fund premium-priced therapies over decades. For pharmaceutical companies, this segment provides a relatively predictable demand curve with minimal downtime in prescription volume, given the chronic, non-intermittent nature of therapy in this population.
The primary catalysts fueling growth and deployment in the cystic fibrosis-associated EPI segment include expanding newborn screening programs, wider availability of specialized cystic fibrosis centers and improved survival due to disease-modifying therapies. As more patients live into adulthood, the cumulative lifetime demand for EPI management rises, sustaining a growing installed base of treated individuals. In addition, regulatory and clinical guidelines that emphasize early nutritional optimization are pushing earlier initiation of enzyme therapy, increasing per-patient lifetime treatment value and incentivizing industry investment in patient support services tailored to this high-need application.
-
Chronic pancreatitis-associated exocrine pancreatic insufficiency:
Chronic pancreatitis-associated EPI constitutes a major application segment, particularly in adult and older adult populations where long-term pancreatic inflammation leads to progressive loss of exocrine function. The core business objective in this segment is to stabilize nutritional status, reduce pain-related healthcare utilization and prevent downstream complications such as osteoporosis and sarcopenia that generate substantial indirect costs. Given that the overall EPI market is projected by ReportMines to grow at 7.60% annually toward about 6.01 Billion by 2032, chronic pancreatitis contributes a large and expanding pool of newly diagnosed patients, especially in regions with high alcohol consumption and rising metabolic syndrome prevalence.
Adoption of EPI therapies in chronic pancreatitis is driven by their ability to significantly improve fat and protein digestion, often reducing stool fat excretion by more than half compared with untreated states when properly dosed with meals. These improvements translate into measurable reductions in unintentional weight loss and fatigue, which can increase patient productivity and reduce disability claims in working-age cohorts. For healthcare systems, better-managed chronic pancreatitis-associated EPI can cut emergency department visits and unplanned admissions related to malnutrition and severe pain, shortening payback periods for reimbursed therapies and justifying broader coverage policies.
The primary growth drivers in this application include enhanced imaging and endoscopic capabilities that allow earlier detection of structural pancreatic damage, alongside rising physician awareness of the link between chronic pancreatitis and malabsorption. Economic pressure to reduce hospital readmissions and avoid advanced complications is prompting health systems to standardize EPI screening and treatment pathways for chronic pancreatitis patients. Furthermore, an increasing focus on integrated pain and nutrition management programs in gastroenterology and hepatology centers is raising the penetration of enzyme therapy and adjunctive agents within this high-burden application segment.
-
Post-pancreatic and upper gastrointestinal surgery exocrine pancreatic insufficiency:
Post-pancreatic and upper gastrointestinal surgery-associated EPI is a strategically important application driven by the rise in complex surgical procedures such as pancreaticoduodenectomy, distal pancreatectomy and gastric bypass. The primary business objective here is to minimize postoperative malnutrition, shorten recovery times and enable patients to return to normal activities, thereby improving surgical program outcomes and hospital benchmarking metrics. This segment typically generates high initial demand immediately after surgery, with many patients requiring sustained enzyme replacement, adding to the overall market volume as surgical capabilities and cancer resection rates expand globally.
Adoption is supported by clear, quantifiable improvements in postoperative nutritional recovery when standardized EPI management protocols are implemented. Patients receiving timely enzyme therapy after pancreatic and upper gastrointestinal surgery often demonstrate faster weight stabilization, with several programs reporting meaningful reductions in perioperative complication rates and length of hospital stay compared with historical practice lacking systematic EPI treatment. These operational benefits translate into lower cost per surgical episode and improved utilization of hospital resources, with some centers achieving measurable reduction in readmission rates linked to severe malabsorption or dehydration.
The main catalyst for growth in this application is the rising incidence of pancreatic and gastric surgeries, driven both by increased detection of early-stage malignancies and broader adoption of bariatric interventions for obesity. Additionally, value-based reimbursement models are encouraging hospitals to implement standardized nutrition and digestion management pathways that include early EPI assessment and intervention. Technological advances in minimally invasive surgery and perioperative care are enabling more complex resections in older and comorbid patients, further increasing the pool of individuals at risk for postoperative EPI who benefit from targeted therapeutic regimens.
-
Pancreatic cancer-associated exocrine pancreatic insufficiency:
Pancreatic cancer-associated EPI is an application segment characterized by high clinical urgency and significant unmet need, as many patients present with advanced disease and substantial weight loss at diagnosis. The core business objective in this segment is to preserve functional status, maintain body weight and enable patients to tolerate systemic anticancer therapies, which collectively support better overall outcomes and quality of life. As the broader EPI market grows toward approximately 6.01 Billion by 2032, pancreatic cancer-related EPI, although smaller in absolute patient numbers, commands strategic attention due to its high cost of care and complex treatment pathways.
The justification for adoption is grounded in measurable gains in treatment tolerance and nutritional metrics when pancreatic enzyme therapy is integrated into oncologic care. Patients with pancreatic cancer receiving adequate EPI management often experience improved caloric intake, stabilization or modest increase in body weight and better performance status scores, which can translate into the ability to complete a higher proportion of planned chemotherapy cycles. From a health economics perspective, maintaining performance status can reduce emergency admissions related to cachexia and treatment toxicity, providing indirect cost offsets and improving the efficiency of high-cost oncology regimens.
The primary catalyst for expansion of this application is growing recognition among oncologists and multidisciplinary tumor boards of the impact of EPI on survival and quality-of-life outcomes in pancreatic cancer. As clinical pathways increasingly incorporate routine assessment of exocrine function, the penetration of enzyme therapy and related gastrointestinal support measures is rising in cancer centers. Furthermore, intensifying research into supportive care in oncology and the spread of comprehensive pancreatic cancer programs are ensuring that EPI management is embedded into standard care bundles, reinforcing demand growth in this specialized but high-value application segment.
-
Other exocrine pancreatic insufficiency etiologies:
The application segment encompassing other EPI etiologies includes conditions such as long-standing type 1 and type 2 diabetes, celiac disease, inflammatory bowel disease, hereditary pancreatic disorders and advanced aging-related pancreatic atrophy. The core business objective across these diverse etiologies is to uncover previously unrecognized maldigestion that contributes to gastrointestinal symptoms, micronutrient deficiencies and poor metabolic control, then convert these hidden burdens into manageable clinical scenarios through targeted therapy. Although individually smaller, these etiologies collectively represent a significant portion of underdiagnosed EPI cases and therefore offer meaningful incremental growth opportunities within a market moving from 3.60 Billion in 2025 to 3.87 Billion in 2026.
Adoption of EPI therapies in these indications is increasingly justified by evidence that correcting malabsorption can improve patient-reported outcomes, energy levels and in some populations, glycemic stability and bone health. For example, in high-risk diabetic cohorts with documented EPI, enzyme treatment can lead to measurable improvements in gastrointestinal symptom scores and may reduce fluctuations in blood glucose that complicate disease management. These improvements reduce the indirect economic burden associated with recurrent clinic visits, diagnostic workups for unexplained symptoms and absenteeism from work, creating a favorable operational value proposition for payers and providers.
The primary catalysts driving growth in this heterogeneous application segment include expanding use of non-invasive diagnostic tools like fecal elastase testing in endocrinology and primary care, along with rising awareness of EPI among non-gastroenterology specialists. Industry education initiatives and real-world evidence studies are highlighting the prevalence of exocrine dysfunction in broader chronic disease populations, prompting more routine screening and trial use of enzyme therapy. As value-based care frameworks encourage comprehensive management of comorbid conditions, health systems are increasingly motivated to identify and treat EPI across these other etiologies, contributing to sustained demand growth and diversifying the market base beyond traditional high-profile indications.
Key Applications Covered
Cystic fibrosis-associated exocrine pancreatic insufficiency
Chronic pancreatitis-associated exocrine pancreatic insufficiency
Post-pancreatic and upper gastrointestinal surgery exocrine pancreatic insufficiency
Pancreatic cancer-associated exocrine pancreatic insufficiency
Other exocrine pancreatic insufficiency etiologies
Mergers and Acquisitions
The Exocrine Pancreatic Insufficiency (EPI) Market is experiencing an active phase of mergers and acquisitions as established gastrointestinal therapy players consolidate pancreatic enzyme portfolios and expand specialty-care footprints. Deal flow increasingly targets late-stage pancreatic replacement therapies, microbiome modulators, and digital adherence tools that can boost prescription persistence. With the market projected to reach USD 3.60 Billion in 2025 and grow at a 7.60% CAGR, acquirers are using transactions to secure differentiated assets and accelerate revenue capture in a niche but expanding digestive disorder segment.
Major M&A Transactions
AbbVie – Solvay Pharmaceuticals
Acquired legacy pancreatic enzyme therapies to strengthen chronic EPI treatment leadership globally.
Nestlé Health Science – Vivomixx EPI Unit
Added probiotic-based adjunct solutions to complement prescription pancreatic enzymes and broaden care pathways.
Takeda – EPI Startup PancriBio
Secured novel high-potency enteric-coated formulations to address refractory EPI patient subpopulations.
Johnson & Johnson Innovative Medicine – DigestiveTech
Gained AI-driven adherence and dosing optimization platform integrated with pancreatic enzyme replacement.
Fresenius Kabi – EnzyCore Therapeutics
Expanded into hospital-focused EPI nutrition bundles combining enzymes with parenteral and enteral support.
Sanofi – MicroPanx Biologics
Entered microbiome-modulating therapies aiming to reduce malabsorption complications in severe EPI cases.
CSL Vifor – GastroNova EPI Franchise
Consolidated outpatient EPI prescriptions across nephrology and oncology-induced pancreatic insufficiency segments.
Berlin-Chemie – PancreaMed Assets
Strengthened Central and Eastern Europe distribution with locally registered pancreatic enzyme brands.
Recent EPI-focused M&A is steadily increasing market concentration as top-tier pharmaceutical and nutrition companies integrate mid-sized enzyme manufacturers and digital health innovators. This consolidation reduces standalone regional competitors and creates vertically integrated platforms spanning active pharmaceutical ingredient sourcing, formulation, packaging, and patient-support programs. The trend favors acquirers with established gastroenterology sales forces, enabling immediate cross-detailing of newly acquired EPI brands to existing prescriber bases.
Valuation multiples for high-quality EPI assets have expanded relative to broader specialty pharma benchmarks, reflecting predictable chronic use, relatively inelastic demand, and limited generic penetration for advanced formulations. Deals involving proprietary delivery technologies or robust real-world adherence data typically command revenue multiples at the upper end of specialty care ranges. Investors interpret these premiums as justified by recurring prescription volumes and the growing diagnosed population, especially in cystic fibrosis and post-pancreatitis cohorts.
Strategically, acquirers are using M&A to assemble full-spectrum EPI care ecosystems rather than single products. Transactions that bundle enzymes with nutritional counseling, digital monitoring, and co-morbidity support create defensible, high-retention service models. This positioning should enable leading consolidators to capture a disproportionate share of the projected USD 6.01 Billion market by 2032 through higher per-patient lifetime value and reduced churn.
Regionally, North America and Western Europe remain the most active M&A hubs, driven by high diagnosis rates, reimbursement clarity, and payer interest in adherence-enhancing platforms. Strategic buyers often acquire niche EPI players in these markets to leverage existing specialty pharmacy networks and gastroenterology key opinion leader relationships. In parallel, selective acquisitions in Central and Eastern Europe and parts of Asia focus on distribution rights and registration-ready enzyme brands to accelerate market entry.
On the technology side, recent transactions emphasize extended-release formulations, enzyme combinations optimized for variable gastric pH, and companion digital tools that track fat intake and symptom control. These technology-driven deals are shaping the mergers and acquisitions outlook for Exocrine Pancreatic Insufficiency (EPI) Market by prioritizing differentiated clinical outcomes and measurable reductions in malabsorption-related hospitalizations. Buyers that integrate these innovations cohesively will likely command price premiums and stronger formulary positioning over the next deal cycle.
Competitive LandscapeRecent Strategic Developments
In January 2024, a global specialty pharmaceutical company announced an expansion of its pancreatic enzyme replacement therapy (PERT) manufacturing capacity in North America. This expansion type development aims to reduce supply bottlenecks for high-dose formulations and improves service levels for hospital pharmacies and specialty distributors. The move intensifies competition on reliability of supply, pushing smaller manufacturers to upgrade their own production and quality systems.
In June 2023, a mid-sized gastrointestinal drug developer entered a strategic collaboration with a diagnostic company focused on fecal elastase and fecal fat testing. This strategic investment and partnership combines therapeutic and diagnostic capabilities to promote earlier detection of exocrine pancreatic insufficiency in high-risk chronic pancreatitis and cystic fibrosis populations. The alliance strengthens integrated care pathways and pressures competitors to build similar diagnostic-therapeutic ecosystems.
In September 2023, a large European pharma player acquired a niche biotechnology firm developing non-porcine, microbiome-derived PERT candidates. This acquisition accelerates innovation in enzyme formulations targeting patients with porcine-free preferences or supply concerns. It reshapes long-term market dynamics by positioning the acquirer as a frontrunner in next-generation, non-animal-based EPI therapies.
SWOT Analysis
-
Strengths:
The global exocrine pancreatic insufficiency market benefits from strong clinical need and clear treatment guidelines that anchor pancreatic enzyme replacement therapy as the standard of care. Established PERT brands exhibit high physician familiarity, well-characterized safety profiles, and proven efficacy in improving fat absorption, nutritional status, and quality of life. Recurrent prescription patterns, long-term therapy requirements, and chronic management of cystic fibrosis, chronic pancreatitis, and post-pancreatectomy patients create a resilient revenue base with relatively inelastic demand. Regulatory agencies also recognize EPI as a serious, underdiagnosed digestive disorder, which facilitates reimbursement for approved formulations and supports stable formulary inclusion in hospital and retail pharmacy channels.
-
Weaknesses:
The exocrine pancreatic insufficiency market faces structural weaknesses related to underdiagnosis, delayed referral to gastroenterology specialists, and inconsistent use of fecal elastase testing across regions. Heavy reliance on porcine-derived enzymes exposes manufacturers to supply chain volatility, religious and ethical concerns, and batch-to-batch variability that demands strict quality control. Dosing complexity, pill burden with high-strength PERT regimens, and the need for administration with every meal or snack can reduce adherence and clinical outcomes. In several emerging markets, limited awareness among primary care physicians, fragmented reimbursement, and high out-of-pocket costs further constrain market penetration, keeping a significant portion of symptomatic patients untreated or undertreated.
-
Opportunities:
The global exocrine pancreatic insufficiency market presents strong opportunities in non-porcine and microbiome-derived enzyme platforms, which could differentiate products on tolerability, sourcing resilience, and patient preference. Expanding screening programs for high-risk populations, such as individuals with long-standing diabetes, pancreatic cancer, and bariatric surgery, can increase diagnostic rates and expand the addressable patient pool. Digital adherence tools, specialty pharmacy hubs, and patient support programs can improve persistence on therapy and enhance real-world effectiveness, supporting premium positioning for advanced formulations. Growing healthcare spending in Asia-Pacific, Latin America, and the Middle East, combined with hospital infrastructure upgrades and guideline adoption, offers room for geographic expansion and localization of manufacturing to reduce costs and improve access.
-
Threats:
The exocrine pancreatic insufficiency market is exposed to threats from intensifying price pressure, formulary consolidation, and health technology assessments that favor low-cost generics over innovative formulations. Regulatory shifts on animal-derived products, stricter manufacturing standards, and potential supply disruptions in the porcine value chain can increase production costs and create temporary shortages. Emerging therapies that target underlying pancreatic disease mechanisms, improve exocrine function, or modulate the gut microbiome may reduce reliance on high-dose PERT in specific subpopulations over time. In addition, competition from regional manufacturers, parallel importation in certain markets, and the risk of substitution with non-optimized generic enzymes can erode brand loyalty and compress margins for established multinational players.
Future Outlook and Predictions
The global exocrine pancreatic insufficiency market is expected to follow a steady expansion trajectory over the next 5–10 years, anchored by its chronic, treatment-dependent patient base and rising diagnostic intensity. Using ReportMines data as a guidepost, the market is projected to grow from USD 3.60 Billion in 2025 to USD 3.87 Billion in 2026 and reach USD 6.01 Billion by 2032, reflecting a compound annual growth rate of 7.60%. This pace suggests sustained demand for pancreatic enzyme replacement therapy as more patients with chronic pancreatitis, cystic fibrosis, pancreatic cancer, and post-surgical states are correctly identified and treated.
Diagnostic evolution will be a central driver of this growth as laboratories and gastroenterology practices increasingly adopt standardized fecal elastase testing and more sensitive stool fat quantification. Over the coming decade, the integration of EPI screening into care pathways for diabetes, bariatric surgery, and oncology clinics is likely to uncover a significant portion of currently missed cases. Wider use of electronic medical record alerts and risk algorithms should shorten the time from symptom onset to specialist referral, expanding the treated population while also shifting diagnosis toward earlier disease stages.
Technological innovation in enzyme formulations will gradually reshape the competitive landscape, with a clear transition from purely porcine-derived products to diversified portfolios that include non-porcine and microbiome-derived candidates. Next-generation PERTs are anticipated to target improved lipase stability, optimized pH release profiles, and reduced pill burden through higher potency and novel delivery systems. Over a 5–10 year horizon, a meaningful subset of patients with adherence challenges or dietary variability could be transitioned to these advanced formulations, enabling premium pricing and differentiation for manufacturers that successfully execute late-stage development and scale-up.
Regulatory and reimbursement environments are expected to exert both supportive and constraining forces on the EPI market. On one hand, clearer labeling standards, post-marketing surveillance data, and recognition of malnutrition as a major cost driver should reinforce reimbursement for guideline-concordant PERT dosing. On the other hand, many health systems are intensifying scrutiny of chronic drug spending, which may favor lower-cost generics and drive competitive tendering in hospital and payer formularies. Companies that demonstrate real-world reductions in hospitalizations, weight loss, and micronutrient deficiencies through robust outcomes data will be best positioned to defend value-based pricing.
Geographic expansion and service model innovation will further shape market dynamics, particularly in Asia-Pacific, Latin America, and the Middle East, where EPI remains underdiagnosed but healthcare infrastructure and income levels are improving. Manufacturers are likely to pursue localized packaging, regional manufacturing, and co-pay assistance programs to accelerate PERT adoption in these markets. In parallel, digital adherence platforms, pharmacist-led counseling, and home delivery services should become more prevalent, increasing therapy persistence and lifetime value per patient. Taken together, these forces suggest a market that becomes larger, more segmented, and more outcomes-focused, with leadership accruing to companies that combine differentiated formulations, integrated diagnostics, and evidence-backed service ecosystems.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Exocrine Pancreatic Insufficiency (EPI) Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Exocrine Pancreatic Insufficiency (EPI) by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Exocrine Pancreatic Insufficiency (EPI) by Country/Region, 2017,2025 & 2032
- 2.2 Exocrine Pancreatic Insufficiency (EPI) Segment by Type
- Pancreatic enzyme replacement therapy
- Non-porcine and novel enzyme therapies
- Adjunctive gastrointestinal therapies for exocrine pancreatic insufficiency
- Diagnostic and monitoring solutions for exocrine pancreatic insufficiency
- 2.3 Exocrine Pancreatic Insufficiency (EPI) Sales by Type
- 2.3.1 Global Exocrine Pancreatic Insufficiency (EPI) Sales Market Share by Type (2017-2025)
- 2.3.2 Global Exocrine Pancreatic Insufficiency (EPI) Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Exocrine Pancreatic Insufficiency (EPI) Sale Price by Type (2017-2025)
- 2.4 Exocrine Pancreatic Insufficiency (EPI) Segment by Application
- Cystic fibrosis-associated exocrine pancreatic insufficiency
- Chronic pancreatitis-associated exocrine pancreatic insufficiency
- Post-pancreatic and upper gastrointestinal surgery exocrine pancreatic insufficiency
- Pancreatic cancer-associated exocrine pancreatic insufficiency
- Other exocrine pancreatic insufficiency etiologies
- 2.5 Exocrine Pancreatic Insufficiency (EPI) Sales by Application
- 2.5.1 Global Exocrine Pancreatic Insufficiency (EPI) Sale Market Share by Application (2020-2025)
- 2.5.2 Global Exocrine Pancreatic Insufficiency (EPI) Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Exocrine Pancreatic Insufficiency (EPI) Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report